Drug Target Review

JULY 12, 2023

Molecular-level biochemical assays like transcriptomics, genomics and proteomics have emerged as valuable tools for identifying potential targets in cancer treatment through deep cyclic inhibition (DCI). Author Bio: Brett Hall Brett has been Chief Scientific Officer at Immuneering since November 2019.

Biochemical Assays 98

Biochemical Assays Treatment Bioinformatics Disease 98

Drug Target Review

NOVEMBER 1, 2023

I work in the Centre for Cancer Drug Discovery (CCDD) at The Institute of Cancer Research in London, which is an academic drug discovery centre. The mission of the CCDD is to discover novel small-molecule therapeutics for the treatment of cancer and progress them to hypothesis testing phase 1 clinical trials.

Fragment Screening 96

Fragment Screening Biochemical Assays Small Molecule Biophysical Assays 96

PerkinElmer

FEBRUARY 18, 2021

Industry leaders reveal how high throughput screening is changing in R&D What do you think are the major trends in drug discovery R&D? Small screens are better than large ones. Biochemical assays have the highest success rate. Small molecules are making a comeback. Biologics are booming. Think again.

Biochemical Assays 52

Biochemical Assays Drugs Small Molecule Pharma Companies 52